Skorpios Trust
LIMASSOL, G4
$53m in 2 US stocks at the end of 30 September 2025. The top 10 are 100.0% of the money. It changed about 0.1% of the portfolio this quarter.
Value
$53m
Stocks
2
Top 10 share
100.0%
Turnover
0.1%
What changed this quarter
New
Bought for the first time this quarter.
None this quarter.
Added
Bought more of a stock they already held.
None this quarter.
Cut
Sold some of their stake.
- Stoke TherapeuticsSTOK99.7% of the fund-31%
Sold out
Sold their entire stake.
None this quarter.
Holdings
- Spdr Series TrustXBI
- Share
- 0.3%
- Value
- $168,937
- Shares
- 1,686
Held
| Company | Share of fund | Value | Shares | Change |
|---|---|---|---|---|
| Stoke TherapeuticsSTOK | 99.7% | $53m | 2,256,181 | -31% |
| Spdr Series TrustXBI | 0.3% | $168,937 | 1,686 | Held |
Over time and by industry
Value over time
Sep '25
Value is up 43.4% since 30 June 2025.
Where the money is
Health care99.7%
Other0.3%
From the fund's 13F filings. They list US stocks and options only, 45 days after each quarter, and leave out cash, bonds, shorts and foreign shares.